Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo

International Journal of Cancer

Volumn 73, Issue 5, 1997, Pages 729-734

  Guichard, Sylvie ^a,b   Cussac, Daniel ^a,b   Hennebelle, Isabelle ^a   Bugat, Roland ^a,b   Canal, Pierre ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; FLUOROURACIL; IRINOTECAN;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL DEATH; CELL STRAIN HT29; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; HUMAN; MOUSE; NUDE MOUSE; PATHOLOGY; SURVIVAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL DEATH; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FLUOROURACIL; HT29 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; SURVIVAL ANALYSIS;

EID: 0031588364     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19971127)73:5<729::aid-ijc20>3.0.co;2-%23     Document Type: Article

References (22)

1. ASCHELE, C., BALDO, C., GUGLIELMI, A., SOBRERO, A. and BERTINO, J.R., Sequence-dependent synergism between tomudex and irinotecan in human colon-cancer cells in vitro. 9th NCi EORTC Symposium on new drugs in cancer therapy. 302, 88 (1996).
2. BASERGA, R., The cell cycle: myths and realities. Cancer Res., 50, 6769-6771 (1990).
3. BOOTHMAN, D.A., FUKUNAGA, N. and WANG, M., Down-regulation of topoisamerase I in mammalian cells following ionizing radiation. Cancer Res., 54, 4618-4626 (1994).
4. CHOU, T.C. and TALALAY, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advanc. Enzyme Regul., 22, 27-55 (1984).
5. ERLICHMAN, C., SVINGEN, P.A., MULLANY, S.A. and KAUFMANN, S.H., Synergistic interaction of SN-38 and 5FU/leucovorin. Proc. Amer. Assoc. Cancer Res., 37, 294 (1996).
6. GOLDWASSER, F., VALENTI, M., TORRES, R., KOHN, K.W. and POMMIER, Y., Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin. Cancer Res., 2, 687-693 (1996).
7. HOUGHTON, J.A., CHESHIRE, P.J., HALLMAN, J.D.N., LUTZ, L., LUO, X., LI, Y. and HOUGHTON, P.J., Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin. Cancer Res., 2, 107-118 (1996).
8. HOUGHTON, P.J., CHESHIRE, P.J., HALLMAN, J.D.N., LUTZ, L., FRIEDMAN, H.S., DANKS, M.K. and HOUGHTON, J.A., Efficacy of topoisomerase-I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36, 393-403 (1995).
9. JANSEN, W.J.M., ZWART, B., HULSCHER, S.T.M., GIACONNE, G., PINEDO, H.M. and BOVEN, E., CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int. J. Cancer, 70, 335-340 (1997).
10. KANO, Y., SUZUKI, K., AKUTSU, M., SUDA, K., INOUE, Y., YOSHIDA, M., SAKAMOTO, S. and MIURA, Y., Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer, 50, 604-610 (1992).
11. KAUFMANN, S.H., PEEREBOOM, D., BUCKWALTER, C.A., SVINGEN, P.A., GROCHOW, L.B., DONEHOWET, R.C. and ROWINSKY, E.K., Cytotoxic effects of topotecan combined with various anti-cancer agents in human cancer cell lines. J. nat. Cancer Inst., 88, 734-741 (1996).
12. KAWATO, Y., AONUMA, M., HIROTA, Y., KUGA, H. and SATO, K., Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the anti-tumor effect of CPT-11, Cancer Res., 51, 4187-4191 (1991).
13. LONN, U. and LONN, S., Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. Cancer Res., 44, 3414-3418 (1984).
14. MANS, D.R.A., BRONDANI DA ROCHA, A., VARGAS SCHWARTZBOLD, C. and SCHWARTSMANN, G., Assessment of the efficacy of the irinotecan-5-fluorouracil combination in a panel of human colon-carcinoma cell lines. Proc. Amer. Ass. Cancer Res., 37, 291 (1996).
15. NAGUIB, F.N.M., HAO, S.N. and EL KOUNI, M.H., Potentiation of 5-fluorouracil efficacy by the dihydrouracil-dehydrogenase inhibitor, 5-benzyloxybenzyluracil. Cancer Res., 54, 5166-5170 (1994).
16. RIVORY, L.P. and ROBERT, J., Molecular, cellular and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol. Ther., 68, 269-296 (1995).
17. ROUGIER, P. and BUGAT, R., CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin. Oncol., 23, 34-41 (1996).
18. ROUGIER, P. and 21 OTHERS, Phase-II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients treated with fluorouracil-based chemotherapy. J. Clin. Oncol., 15, 251-260 (1997).
19. SALTZ, L.B., KANOWITZ, J., KEMENY, N.E., SCHAAF, L., SPRIGGS, D., STATON, B.A., BERKERY, R., STEGER, C., ENG, M., DIETZ, A., LOCKER, P. and KELSEN, D.P., Phase-I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumors. J. Clin. Oncol., 14, 2959-2967 (1996).
20. SCHUETZ, J.D., WALLACE, H.J. and DIASIO, R.B., 5-fluorouracil incorporation into DNA of CF-1 bone-marrow cells as a possible mechanism of toxicity. Cancer Res., 44, 1358-1363 (1984).
21. SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS, A., MCMAHON, J., VISTICA, D., WARREN, J.T., BOKESCH, H., KENNEY, S. and BOYD, M.R., New colorimetric cytotoxicity assay tor anti-cancer-drug screening. J. nat. Cancer Inst., 82, 1107-1112 (1990).
22. VASSAL, G., TERRIER-LACOMBE, M.J., BISSERY, M.C., VENUAT, A.M., GYERGYAY, F., BENARD, J., MORIZET, J., BOLAND, I., ARDOUIN, P., BRESSAC DE PAILLERETS, B. and GOUYETTE, A., Therapeutic activity of CPT-11, a DNA-topoisomerase-I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Brit. J. Cancer, 74, 537-545 (1996).